Previously enrolled in this study (i.e. patient now at repeat encounter)
Concomitant surgical procedure other than CABG
Anticoagulant treatment after the operation (e.g. warfarin, direct thrombin inhibitors (dabigatran), FXa inhibitors (rivaroxaban, apixaban, heparin, low-molecular weight heparin, fondaparinux)
Discharge from the operating hospital to an ICU at another hospital
Pregnancy or lactation
Known intolerance or contraindication to ticagrelor or ASA
Any disorder that may interfere with drug absorption
Any condition other than coronary artery disease with a life expectancy <12 months
Known chronic liver disease, renal disease requiring dialysis or bleeding disorder
Atrioventricular block II and III in patients without pacemaker
Any other indication for dual antiplatelet therapy, i.e. recent stent implantation
Debilitating stroke within 90 days before inclusion
Previous intracranial bleeding
Treatment with immunosuppressants (e.g. cyclosporine and tacrolimus)
Treatment with strong CYP3A4-inhibitors (e.g. ketoconazole, clarithromycin, nefazodone, ritonavir or atazanavir)
Any condition that in the opinion of the investigator may interfere with adherence to trial protocol

NCT03560310_exc_T1
Observation
enrolled in this study
NCT03560310_exc_T2
Temporal
Previously
NCT03560310_exc_T3
Procedure
surgical procedure
NCT03560310_exc_T4
Temporal
Concomitant
NCT03560310_exc_T5
Procedure
CABG
NCT03560310_exc_T6
Qualifier
other than
NCT03560310_exc_T7
Procedure
Anticoagulant treatment
NCT03560310_exc_T8
Temporal
after the operation
NCT03560310_exc_T9
Reference_point
the operation
NCT03560310_exc_T10
Procedure
operation
NCT03560310_exc_T11
Drug
warfarin
NCT03560310_exc_T12
Drug
direct thrombin inhibitors
NCT03560310_exc_T13
Drug
dabigatran
NCT03560310_exc_T14
Drug
FXa inhibitors
NCT03560310_exc_T15
Drug
rivaroxaban
NCT03560310_exc_T16
Drug
apixaban
NCT03560310_exc_T17
Drug
heparin
NCT03560310_exc_T18
Drug
low-molecular weight heparin
NCT03560310_exc_T19
Drug
fondaparinux
NCT03560310_exc_T20
Scope
rivaroxaban, apixaban, heparin, low-molecular weight heparin, fondaparinux
NCT03560310_exc_T21
Scope
warfarin, direct thrombin inhibitors (dabigatran), FXa inhibitors (rivaroxaban, apixaban, heparin, low-molecular weight heparin, fondaparinux
NCT03560310_exc_T22
Observation
Discharge
NCT03560310_exc_T23
Visit
operating hospital
NCT03560310_exc_T24
Visit
ICU
NCT03560310_exc_T25
Qualifier
another
NCT03560310_exc_T26
Visit
hospital
NCT03560310_exc_T27
Scope
ICU at another hospital
NCT03560310_exc_T28
Condition
Pregnancy
NCT03560310_exc_T29
Condition
lactation
NCT03560310_exc_T30
Condition
contraindication
NCT03560310_exc_T31
Condition
intolerance
NCT03560310_exc_T32
Drug
ticagrelor
NCT03560310_exc_T33
Drug
ASA
NCT03560310_exc_T34
Scope
intolerance or contraindication
NCT03560310_exc_T35
Scope
ticagrelor or ASA
NCT03560310_exc_T36
Condition
disorder
NCT03560310_exc_T37
Qualifier
may interfere with drug absorption
NCT03560310_exc_T38
Condition
coronary artery disease
NCT03560310_exc_T39
Negation
other than
NCT03560310_exc_T40
Condition
condition
NCT03560310_exc_T41
Observation
life expectancy
NCT03560310_exc_T42
Value
<12 months
NCT03560310_exc_T43
Condition
chronic liver disease
NCT03560310_exc_T44
Condition
renal disease
NCT03560310_exc_T45
Procedure
dialysis
NCT03560310_exc_T46
Condition
bleeding disorder
NCT03560310_exc_T47
Mood
requiring
NCT03560310_exc_T48
Condition
Atrioventricular block II
NCT03560310_exc_T49
Condition
ricular block II and I tie
NCT03560310_exc_T50
Negation
without
NCT03560310_exc_T51
Device
pacemaker
NCT03560310_exc_T52
Condition
dual antiplatelet therapy
NCT03560310_exc_T53
Procedure
stent implantation
NCT03560310_exc_T54
Temporal
recent
NCT03560310_exc_T55
Condition
indication
NCT03560310_exc_T56
Scope
indication for dual antiplatelet therapy
NCT03560310_exc_T57
Scope
recent stent implantation
NCT03560310_exc_T58
Temporal
within 90 days before inclusion
NCT03560310_exc_T59
Condition
stroke
NCT03560310_exc_T60
Condition
Debilitating
NCT03560310_exc_T61
Temporal
Previous
NCT03560310_exc_T62
Procedure
intracranial bleeding
NCT03560310_exc_T63
Drug
immunosuppressants
NCT03560310_exc_T64
Drug
cyclosporine
NCT03560310_exc_T65
Drug
tacrolimus
NCT03560310_exc_T66
Scope
cyclosporine and tacrolimus
NCT03560310_exc_T67
Drug
strong CYP3A4-inhibitors
NCT03560310_exc_T68
Drug
ketoconazole
NCT03560310_exc_T69
Drug
clarithromycin
NCT03560310_exc_T70
Drug
nefazodone
NCT03560310_exc_T71
Drug
ritonavir
NCT03560310_exc_T72
Drug
atazanavir
NCT03560310_exc_T73
Scope
ketoconazole, clarithromycin, nefazodone, ritonavir or atazanavir